30
Mar

Four months after Pfizer stepped up with a $2.85 billion promise to partner with Merck KGaA on a preclinical PD-L1 oncology effort, the German pharma company has turned around to partner with Intrexon on an upstart CAR-T cancer drug development project.

…read more

Source: UPDATED: Merck KGaA forges a $941M CAR-T development deal with Intrexon

    

0 No comments